Phio Pharmaceuticals (NASDAQ:PHIO – Free Report) had its price objective reduced by HC Wainwright from $6.00 to $4.00 in a report released on Tuesday morning, Benzinga reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for Phio Pharmaceuticals’ Q4 2023 earnings at ($1.30) EPS, FY2023 earnings at ($6.26) […]
Checkpoint Inhibitors Clinical Trial Pipeline Insights | 180+ Key Companies Investigating Their Lead Candidates to Improve the Treatment Space | medgadget.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medgadget.com Daily Mail and Mail on Sunday newspapers.
Investment Analysts’ price target changes for Tuesday, February 6th: AbbVie (NYSE:ABBV) had its price target increased by Truist Financial Co. from $180.00 to $195.00. The firm currently has a buy rating on the stock. Barrick Gold (TSE:ABX) (NYSE:ABX) had its target price reduced by National Bankshares, Inc. from C$29.00 to C$28.00. They currently have a […]